Murakami T - Search Results

1

Potent leads based on CA-19L, an anti-HIV active HIV-1 capsid fragment.

Tsuji K, Wang R, Kobayakawa T, Owusu KB, Fujino M, Kaneko M, Yamamoto N, Murakami T, Tamamura H. Tsuji K, et al. Among authors: murakami t. Bioorg Med Chem. 2021 Jan 15;30:115923. doi: 10.1016/j.bmc.2020.115923. Epub 2020 Dec 7. Bioorg Med Chem. 2021. PMID: 33316719

2

Anti-HIV-1 peptides derived from partial amino acid sequences of CC-chemokine RANTES. Regulated upon activation, normal T-cell expressed and secreted.

Nishiyama Y, Murakami T, Shikama S, Kurita K, Yamamoto N. Nishiyama Y, et al. Among authors: murakami t. Bioorg Med Chem. 2002 Dec;10(12):4113-7. doi: 10.1016/s0968-0896(02)00271-7. Bioorg Med Chem. 2002. PMID: 12413865

3

The interaction of HIV-1 with the host factors.

Komano J, Futahashi Y, Urano E, Miyauchi K, Murakami T, Matsuda Z, Yamamoto N. Komano J, et al. Among authors: murakami t. Jpn J Infect Dis. 2005 Jun;58(3):125-30. Jpn J Infect Dis. 2005. PMID: 15973003 Review.

4

Structure-activity relationship study of CXCR4 antagonists bearing the cyclic pentapeptide scaffold: identification of the new pharmacophore.

Tanaka T, Tsutsumi H, Nomura W, Tanabe Y, Ohashi N, Esaka A, Ochiai C, Sato J, Itotani K, Murakami T, Ohba K, Yamamoto N, Fujii N, Tamamura H. Tanaka T, et al. Among authors: murakami t. Org Biomol Chem. 2008 Dec 7;6(23):4374-7. doi: 10.1039/b812029c. Epub 2008 Oct 17. Org Biomol Chem. 2008. PMID: 19005596

5

Substitution of the myristoylation signal of human immunodeficiency virus type 1 Pr55Gag with the phospholipase C-delta1 pleckstrin homology domain results in infectious pseudovirion production.

Urano E, Aoki T, Futahashi Y, Murakami T, Morikawa Y, Yamamoto N, Komano J. Urano E, et al. Among authors: murakami t. J Gen Virol. 2008 Dec;89(Pt 12):3144-3149. doi: 10.1099/vir.0.2008/004820-0. J Gen Virol. 2008. PMID: 19008404 Free PMC article.

6

Efficient inhibition of SDF-1alpha-mediated chemotaxis and HIV-1 infection by novel CXCR4 antagonists.

Iwasaki Y, Akari H, Murakami T, Kumakura S, Dewan MZ, Yanaka M, Yamamoto N. Iwasaki Y, et al. Among authors: murakami t. Cancer Sci. 2009 Apr;100(4):778-81. doi: 10.1111/j.1349-7006.2009.01104.x. Epub 2009 Feb 24. Cancer Sci. 2009. PMID: 19245436 Free article.

7

The novel CXCR4 antagonist KRH-3955 is an orally bioavailable and extremely potent inhibitor of human immunodeficiency virus type 1 infection: comparative studies with AMD3100.

Murakami T, Kumakura S, Yamazaki T, Tanaka R, Hamatake M, Okuma K, Huang W, Toma J, Komano J, Yanaka M, Tanaka Y, Yamamoto N. Murakami T, et al. Antimicrob Agents Chemother. 2009 Jul;53(7):2940-8. doi: 10.1128/AAC.01727-08. Epub 2009 May 18. Antimicrob Agents Chemother. 2009. PMID: 19451305 Free PMC article.

8

BCA2/Rabring7 promotes tetherin-dependent HIV-1 restriction.

Miyakawa K, Ryo A, Murakami T, Ohba K, Yamaoka S, Fukuda M, Guatelli J, Yamamoto N. Miyakawa K, et al. Among authors: murakami t. PLoS Pathog. 2009 Dec;5(12):e1000700. doi: 10.1371/journal.ppat.1000700. Epub 2009 Dec 18. PLoS Pathog. 2009. PMID: 20019814 Free PMC article.

9

Remodeling of dynamic structures of HIV-1 envelope proteins leads to synthetic antigen molecules inducing neutralizing antibodies.

Nakahara T, Nomura W, Ohba K, Ohya A, Tanaka T, Hashimoto C, Narumi T, Murakami T, Yamamoto N, Tamamura H. Nakahara T, et al. Among authors: murakami t. Bioconjug Chem. 2010 Apr 21;21(4):709-14. doi: 10.1021/bc900502z. Bioconjug Chem. 2010. PMID: 20359196

10

Role of CXCR4 in HIV infection and its potential as a therapeutic target.

Murakami T, Yamamoto N. Murakami T, et al. Future Microbiol. 2010 Jul;5(7):1025-39. doi: 10.2217/fmb.10.67. Future Microbiol. 2010. PMID: 20632803 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

5,507 results

Search Page